Bio-Path Holdings, Inc. (BPTH) News

Bio-Path Holdings, Inc. (BPTH): $2.21

0.04 (+1.84%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BPTH to Watchlist
Sign Up

Industry: Biotech


Ranked

of 489

in industry

Filter BPTH News Items

BPTH News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

BPTH News Highlights

  • BPTH's 30 day story count now stands at 4.
  • Over the past 22 days, the trend for BPTH's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • BIO, PATH and LINK are the most mentioned tickers in articles about BPTH.

Latest BPTH News From Around the Web

Below are the latest news stories about BIO-PATH HOLDINGS INC that investors may wish to consider to help them evaluate BPTH as an investment opportunity.

Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q3 2022 Earnings Call Transcript

Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q3 2022 Earnings Call Transcript November 15, 2022 Bio-Path Holdings, Inc. misses on earnings expectations. Reported EPS is $-0.49 EPS, expectations were $-0.45. Operator: Good morning ladies and gentlemen. Welcome to the Bio-Path Holdings Third Quarter 2022 Earnings Conference Call. At this time all participants are in a listen-only mode. Following […]

Yahoo | December 28, 2022

Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors

Phase 1/1b Clinical Trial Evaluating Ability of BP1001-A to Treat Patients with Solid Tumors, Including Ovarian, Endometrial, Pancreatic and Breast Cancer Phase 1/1b Clinical Trial Evaluating Ability of BP1001-A to Treat Patients with Solid Tumors, Including Ovarian, Endometrial, Pancreatic and Breast Cancer

GlobeNewswire | December 7, 2022

Bio-Path Holdings Q3 2022 Earnings Conference Call On November 15, 2022 At 08:30 AM ET

Bio-Path Holdings (NASDAQ: BPTH ) will host a conference call at 08:30 AM ET on November 15, 2022, to discuss Q3 2022 earnings results. How to Attend Bio-Path Holdings (BPTH) Conference Call Follow this link to access the live webcast. To listen to the call, dial (833) 630-1956 (US) or (412) 317-1837 (International) What Is an … Full story available on Benzinga.com

Benzinga | December 6, 2022

Analyzing Bio-Path Holdings''s Short Interest

Bio-Path Holdings''s (NASDAQ: BPTH ) short percent of float has fallen 10.42% since its last report. The company recently reported that it has 34 thousand shares sold short , which is 0.43% of all regular shares that are available for trading. Based on its trading volume, it would take traders 0.8 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price … Full story available on Benzinga.com

Benzinga | November 28, 2022

H.C. Wainwright Reaffirms Their Buy Rating on Bio-Path Holdings (BPTH)

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Bio-Path Holdings (BPTH - Research Report) today and set a price target of $9.00. The company's shares opened today at $1.57.Chen covers the Healthcare sector, focusing on stocks such as Veru, Applied DNA Sciences, and Aslan Pharmaceuticals. According to TipRanks, Chen has an average return of -28.1% and a 24.40% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bio-Path Holdings with a $9.00 average price target.See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $5.28 and a one-year low of $1.29.

Brian Anderson on TipRanks | November 15, 2022

Bio-Path Holdings Reports Third Quarter 2022 Financial Results

Conference Call to be Held Today at 8:30 A.M. ET Conference Call to be Held Today at 8:30 A.M. ET

GlobeNewswire | November 15, 2022

Bio-Path Holdings Inc. (BPTH) Q3 2022 Earnings Call Transcript

Bio-Path Holdings Inc. (NASDAQ:NASDAQ:BPTH) Q3 2022 Earnings Conference Call November 15, 2022, 08:30 AM ET Company Participants Will O''Connor - Stern Investor Relations Peter Nielsen - CEO…

Seeking Alpha | November 15, 2022

Bio-Path Holdings to Announce Third Quarter 2022 Financial Results on November 15, 2022

HOUSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Tuesday, November 15, 2022 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2022 and to provide a business overview.

GlobeNewswire | November 8, 2022

Bio-Path Holdings, Inc. Announces $2.0 Million Registered Direct Offering and Concurrent Private Placement

HOUSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it has entered into a definitive agreement with certain institutional investors for the issuance and sale of 800,000 shares of its common stock (or common stock equivalents) for a price of $2.50 per share, for gross proceeds of

Yahoo | November 7, 2022

Bio-Path Holdings (BPTH) Receives a Buy from H.C. Wainwright

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Bio-Path Holdings (BPTH - Research Report), with a price target of $9.00. The company's shares closed yesterday at $3.30.Chen covers the Healthcare sector, focusing on stocks such as Applied DNA Sciences, Veru, and Belite Bio, Inc. ADR. According to TipRanks, Chen has an average return of -23.0% and a 27.12% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bio-Path Holdings with a $9.00 average price target.See today’s best-performing stocks on TipRanks >>The company has a one-year high of $5.

Brian Anderson on TipRanks | October 27, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7075 seconds.